Rhythm Pharmaceuticals, Inc. (RYTM) Income Statement

The sequential climb suggests the Bardet-Biedl syndrome launch is gaining prescriber and payer momentum, with the acceleration in recent quarters implying the growth is not merely a one-time catch-up. Because the figures do not break out indication-level or geographic revenue, it is unclear how much of the uptick is durable versus driven by timing of gross-to-net adjustments or lumpy international recognition. Investors should monitor whether growth holds once the new hypothalamic obesity launch matures.

The stability of gross margin points to pricing power typical of single-product rare disease therapies, with COGS remaining a small fraction of revenue. The gap between this gross profit and the deeply negative operating margin, which reached -42.6% in the latest quarter after exceeding -140% earlier, indicates that the margin structure is governed almost entirely by operating expenses rather than production economics. Margin expansion therefore depends on revenue scaling faster than the commercial and R&D base.

Operating income improved in the most recent quarters even as SG&A remained elevated near $66-67M, implying revenue is beginning to absorb fixed commercial costs. However, operating expenses have not fallen in absolute terms, so the improvement is driven by top-line growth rather than cost discipline. Whether the company reaches breakeven will hinge on continued revenue growth outpacing a largely fixed SG&A base.

R&D has stayed elevated even as revenue grew, indicating management is prioritizing pipeline expansion over near-term margin improvement. Combined with SG&A near $67M in the latest quarters, total operating spend substantially exceeds gross profit, which the figures suggest is structurally sustained by the current commercial and clinical agenda. The durability of this spending level, rather than its absolute size, will determine how quickly operating losses can narrow.